Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

395
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
395
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

229
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
229
Drug Therapy01:28

Drug Therapy

449
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
449
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

1.9K
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
1.9K
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

423
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
423

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dynamic Risk Trajectories for Sudden Cardiac Arrest: The Role of Recurrent Cardiovascular Events.

Journal of the American Heart Association·2026
Same author

Coronary artery calcium on chest CT scans: from incidental finding to mandatory reporting.

Nature reviews. Cardiology·2026
Same author

Outcomes in the BETAMI-DANBLOCK trial compared with a Norwegian nationwide myocardial infarction population.

European heart journal·2026
Same author

Main Lessons of the Recent Andexanet Withdrawal.

Cardiology·2026
Same author

Patients with lower limb discrepancies-Long-term follow-up, quality of life, and function while mobilizing with Extension-prosthesis.

Prosthetics and orthotics international·2026
Same author

Early Versus Late Initiation of Evolocumab and Arterial Aneurysm Events: An Analysis of FOURIER and FOURIER-OLE.

Circulation·2026
Same journal

Pulmonary Vascular Disease Across the Continuum: From Mechanisms to Precision Care.

Heart failure clinics·2026
Same journal

Long-term Complications of Pulmonary Embolism: Which Is the Optimal Follow-Up?

Heart failure clinics·2026
Same journal

Recent Advances in Pulmonary Hypertension Management.

Heart failure clinics·2026
Same journal

The Role of Machine Learning and Artificial Intelligence in Drug Discovery and Clinical Care of Pulmonary Hypertension.

Heart failure clinics·2026
Same journal

Portopulmonary Hypertension: Current Perspectives.

Heart failure clinics·2026
Same journal

Exercise Training and Cardiac Rehabilitation in Chronic Thromboembolic Pulmonary Hypertension.

Heart failure clinics·2026
See all related articles

Related Experiment Video

Updated: May 1, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

21.0K

Comorbidities and polypharmacy.

Thomas G von Lueder1, Dan Atar1

  • 1Department of Cardiology, Oslo University Hospital Ullevål, University of Oslo, Kirkeveien 166, Oslo 0407, Norway; Institute of Clinical Sciences, University of Oslo, Kirkeveien 166, Oslo 0407, Norway.

Heart Failure Clinics
|March 25, 2014
PubMed
Summary
This summary is machine-generated.

Heart failure (HF) commonly affects elderly patients with multiple comorbidities. Polypharmacy in these patients increases risks and requires new research strategies.

Keywords:
ComorbiditiesElderlyHeart failurePolypharmacy

More Related Videos

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.3K

Related Experiment Videos

Last Updated: May 1, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

21.0K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.3K

Area of Science:

  • Geriatric medicine
  • Cardiology
  • Clinical pharmacology

Background:

  • Heart failure (HF) predominantly impacts the elderly, a population with high comorbidity prevalence.
  • Comorbidities in HF significantly influence patient prognosis.
  • Polypharmacy is increasingly common in HF patients, particularly the elderly, raising concerns about drug interactions and adherence.

Purpose of the Study:

  • To highlight the challenges and implications of polypharmacy in elderly patients with heart failure.
  • To emphasize the need for novel research approaches addressing polypharmacy in HF.

Main Methods:

  • Review of existing literature on heart failure, comorbidities, and polypharmacy in the elderly.
  • Analysis of the prognostic implications of comorbidities and polypharmacy in heart failure management.

Main Results:

  • Elderly HF patients frequently have multiple comorbidities impacting prognosis.
  • Polypharmacy is prevalent and associated with risks like adverse drug interactions and nonadherence.
  • Current clinical trials inadequately address polypharmacy in this demographic.

Conclusions:

  • Polypharmacy in elderly heart failure patients presents significant clinical challenges.
  • There is a critical need for innovative research strategies to investigate and manage polypharmacy in this vulnerable population.